DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

with the injection taking only a few seconds. Laser therapy involves applying small laser pulses to seal leaking blood vessels and reduce macular swelling. Laser therapy can help stabilize and ...

Unity Biotechnology has reported outcomes from its randomised Phase IIb ASPIRE study of intravitreal UBX1325 for diabetic ...

Blindness or vision loss is a growing concern among older adults, and one of the leading causes is a condition known as ...

A team of scientists at the National Institutes of Health (NIH) has developed an eye drop that successfully slowed vision ...

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

UNITY anticipates the complete 36-week data results of the remaining patients in the second quarter of 2025.

Complete 36-week results from the ASPIRE study involving 52 patients are expected in the second quarter of 2025.

The biotech company, focused on developing treatments for chronic eye conditions, received Food and Drug Administration (FDA) ...

A charity dedicated to helping people living with the biggest cause of sight loss, is to host a series of information events in Wrexham.